Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Androgen receptor targeting drugs in castration‐resistant prostate cancer and mechanisms of resistance

2 Sept 2015

Abstract excerpt

Reactivated androgen receptor (AR) signaling drives castration-resistant prostate cancer (CRPC). The novel AR targeting drugs abiraterone and enzalutamide have improved survival of CRPC patients. However, resistance to these agents develops and patients ultimately succumb to CRPC. Potential mechanisms of resistance include the following: 1) Expression of AR splice variants, such as the AR-V7 isoform, which lacks...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Estrogen and related hormone effects
Share to Prostate Cancer Treatment and Research
Share to Radiopharmaceutical Chemistry and Applications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26331358
DOI: 10.1002/cpt.256

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Androgen receptor targeting drugs in castration‐resistant prostate cancer and mechanisms of resistancePMID 26331358Read ↗

Novel hormone therapies for advanced prostate cancer: Understanding and countering drug resistanceSemantic proximity Read ↗

Targeting extra-gonadal androgens in castration-resistant prostate cancer.Semantic proximity Read ↗

Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate CancerSemantic proximity Read ↗

Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approachesSemantic proximity Read ↗

Resistance to second generation antiandrogens in prostate cancer: pathways and mechanismsSemantic proximity Read ↗

Androgen Receptor Signaling in Prostate Cancer and Therapeutic StrategiesSemantic proximity Read ↗

A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509Semantic proximity Read ↗

Persistent androgen receptor addiction in castration-resistant prostate cancerSemantic proximity Read ↗

Targeting the androgen receptor and overcoming resistance in prostate cancerSemantic proximity Read ↗

Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical ApplicationsSemantic proximity Read ↗

Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer.Semantic proximity Read ↗

Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.